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Summary
Kaposi’s sarcoma (KS) is a peculiar vascular neoplasm that occurs mainly in
elderly Mediterranean men and patients with acquired immunodeficiency
syndrome (AIDS). The current literature indicates that KS is initiated by the
human herpes virus 8 (HHV8) as a reactive polyclonal process but with
deregulation of oncogene and tumour suppressor genes, it can progress to a
true malignancy with monoclonality. Clinically, classical KS often presents as
an indolent disease affecting mainly the lower extremities whereas AIDS-related
KS has no site predilection and can progress rapidly with systemic involvement.
Histologically, KS can be classified into patch, plaque and nodular stages.
Interestingly, classical and AIDS-related KS are indistinguishable histologically
and this suggests that AIDS-related KS and classical KS might be initiated by a
common aetiology but given their different clinical courses, they may progress
through different mechanisms. In view of the importance of the cell cycle
proteins in the development and progression of many human malignancies, this
thesis aims to examine the role of these proteins in the progression of the two
main clinical subtypes of KS.
The cell cycle protein expressions in a cohort of 47 patients with KS with well-
documented clinical and histological features were studied. Using a monclonal
antibody against the latent nuclear antigen-1 molecule of HHV8, HHV8 was
detected in 78% of the cases. The more advanced nodular lesions were found
to have a higher level of proliferative activity as measured by the proliferation
xmarker, Ki-67. This suggests it is valid to use the histological specimens as a
tumour progression model of KS.
The role of the Rb/cyclin D1/p16 pathway was examined. The more advanced
nodular stage KS lesions were more likely to be positive for cyclin D1,
suggesting that cyclin D1 is important in the progression from patch stage to
nodular stage. p16 acts as a tumour suppressor and it has an inhibitory effect
on cyclin D1. The p16 expression rate was low in early stage KS but high in the
more advanced lesions. It seems that reduced p16 expression occurs early in
KS and may be important in its development. The rate of Rb expression, on the
other hand, did not differ significantly among the histological subtypes. The
results revealed the significant role of the Rb/cyclin D1/p16 pathway in the
progression of KS.
Of the mitotic cyclins examined, cyclin A expression was correlated with the
advanced tumor stage. The rate of p34cdc2 expression was high in the lesions
and there was no correlation with histological stage. This suggests that p34cdc2
is important in the early development of the tumour but not necessarily in its
progression.
Along the p53-apoptotic pathway, mutant p53 expression was significantly more
common in the nodular stage. The cyclin G1 (a protooncogene, one of the
target genes of p53) expression also paralleled that of mutant p53 with the
majority of the KS lesions showing cyclin G1 expression and significant
xi
correlation between advanced histological stage and increasing rate of cyclin
G1 expression. These findings suggest that progression along the p53 pathway
may be important in the advanced stage development of KS. On the other
hand, expression of the CDK inhibitor, p27, a protein that normally negatively
regulates cyclin G1, was reduced in nodular KS. These findings suggest that
some KS lesions may progress through a deregulated or abnormal p53
pathway.
There were correlations between cyclin D1, cyclin A, cyclin G1, mutant p53 and
negative HIV status. The findings suggest that components of both the
Rb/cyclin D1/p16 and p53-apoptotic pathways are important in the progression
of classical KS.
Rb protein was the only cell cycle protein whose rate of expression correlated
significantly with HHV8 status in KS. The majority of HHV8 positive lesions
were also positive for Rb protein, unlike HHV8 negative lesions. This suggests
that some of the HHV8 negative lesions can progress through a defective Rb
pathway whereas the role of Rb in the progression may not be as important in
the HHV8 positive lesions. This was an unexpected finding given that one of
the postulated mechanisms of tumour initiation by the HHV8 virus is via the viral
cyclin it produces. The viral cyclin produced by HHV8 acts through the Rb
pathway much the same as cyclin D1 and one would have expected that HHV8
positive cases are less likely to be positive for the Rb protein.
xii
In summary, the majority of the KS lesions examined in this thesis show HHV8
infection. The Rb/cyclin D1/p16 pathway appears to be important in the
progression of the different stages of KS and expression of the proteins
involved in the p53 pathway were found to be important in the advanced stages
of the development of KS. There were differential expressions of cell cycle
proteins between AIDS-related and classical KS, and between HHV8 positive
and HHV8 negative lesions. The findings also provided some clues to the
possible mechanisms of development in KS lesions that were not initiated by
HHV8.
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